Viyash Scientific targets $1 billion revenue by 2032
Viyash Scientific Limited announced its goal to become a top 10 global animal health player by 2030, backed by a target of $1 billion in revenue and $250 million in EBITDA by 2032. The company outlined its growth strategy, driven by a robust R&D infrastructure and strategic acquisitions, during its Investor Day 2026.
*this image is generated using AI for illustrative purposes only.
Viyash Scientific Limited outlined its strategic roadmap to become a top 10 animal health player globally by 2030 during its Investor Day 2026 held on June 25, 2026, in Mumbai. The company presented its integrated pharmaceutical platform across animal and human health, backed by science and intellectual property, to stakeholders. Alongside its global ambitions, the company has set concrete financial milestones, targeting $1 billion in revenue and $250 million in EBITDA by 2032, with a return on capital employed (ROCE) of 25% and above.
Strategic Financial Targets
The company's financial roadmap includes a significant contribution from the companion animal segment, which is expected to generate between $150 million and $200 million. These targets reflect the company's intent to scale its integrated pharmaceutical platform and expand its presence across both animal and human health verticals. The following table summarises the key financial goals:
| Target Metric | Value |
|---|---|
| Revenue Target | $1 billion |
| EBITDA Target | $250 million |
| Companion Animal Revenue | $150–200 million |
| ROCE Target | 25%+ |
| Target Year | 2032 |
Company Background and Growth Journey
The presentation highlighted the company's evolution since its founding in February 2019 by Dr. Haribabu Bodepudi. Viyash Scientific expanded rapidly through the acquisitions of Vindhya Pharma, Vandana Life Sciences, Mylan's API and formulation units, Symed Labs, and Appco Pharma LLC. A strategic investment by the Carlyle Group further bolstered its position. The firm has filed over 175 patents and expanded its R&D team to more than 200 scientists.
Dr. Haribabu Bodepudi, the Group CEO, leads the organization with extensive experience in the pharmaceutical industry. Prior to his current role, he served as the CEO of Viyash Life Sciences and held leadership positions at Mylan, including CEO of Mylan India and Global COO. Under his leadership, the company has integrated operations and enhanced its global capabilities following the merger of Viyash Life Sciences with Sequent Scientific.
R&D Infrastructure
The company's R&D infrastructure is a key component of its growth strategy, with centres located in India, Spain, and Turkey. The facilities focus on scalable complex APIs, including high-potent and cytotoxic molecules, as well as formulation development for human and animal health. The table below outlines the R&D capabilities across locations:
| R&D Centre | Location | Capabilities / Dosage Forms | Technologies & Infrastructure | R&D Members |
|---|---|---|---|---|
| API R&D | India (Hyderabad, Telangana) | Scalable complex APIs incl. high-potent (OEB 4/5) & cytotoxic; iron-complex, inorganic & complex molecules | 20+ chemical R&D labs; dedicated process-safety lab; high-end analytical equipment for process dev & validation | 225+ |
| Formulation R&D – Human Health (Viyash / Appco) | India | OSD (Non-Onco) & Onco-Cytotoxic; generics plus complex pharmaceuticals | Formulation development, analytical method development, tech transfer, QA, regulatory affairs | 60+ |
| Formulation R&D – Animal Health (Alivira) | India, Spain, Turkey | Generic & complex dosage forms — solid, liquid & sterile (oral solutions/suspensions, powders, premixes) | Formulation development, analytical method development, tech transfer, QA, regulatory filings | 55+ |
Regulatory Compliance and Risk Disclosure
The company stated that its forward-looking statements regarding the 2030 and 2032 targets are based on current assumptions and involve risks, including economic developments, regulatory changes, and market competition. The presentation was submitted to the exchanges in compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Historical Stock Returns for Viyash Scientific
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.36% | -3.33% | +12.70% | +47.72% | +51.06% | +5.06% |
What specific acquisition targets or geographic markets is Viyash Scientific prioritizing to achieve its goal of becoming a top 10 global animal health player by 2030?
How does the company plan to balance capital allocation between its high-potency human health portfolio and the rapidly growing companion animal segment?
What are the primary regulatory hurdles the company anticipates in the US and European markets for its complex API and formulation pipeline?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
